Pictured: Dr. Hanh Nguyen (Research Officer), Dr. Khashayar Farrokzhad (Senior Research Officer) and Mr. Bill Hopper (Technical Director)
ZiP Diagnostics made its first conference appearance at the recent AusMedtech 2022.
AusMedtech was a two-day conference (25-26 May) which showcased Australia's flourishing medtech network. There were over 450 Australian and international delegates present to discuss this year's theme of "Medtech and Manufacturing".
There was significant interest at the ZiP Diagnostics' booth, with delegates keen to see an Australian-made molecular point-of-care test platform. All main components of the test have been designed, developed and manufactured in Melbourne. ZiP's PC2 laboratory and manufacturing clean rooms are based in Collingwood.
The ZiP-CoVx-P2* test provides a point-of-care result for SARS-CoV-2 within 30 minutes. Clinical trials are currently underway and aims to have performance equivalent to lab-based PCR. Regulatory submissions to Australia's TGA and Europe's IVDR are in preparation.
*The ZiP-CoVx-P2 test is not approved for use in all markets.
Komentarze